Suchen
Repare Therapeutics Inc
RPTXZur Watchlist hinzufügen
2.650USD
0.0000.00%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
114.24MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Repare Therapeutics Inc Unternehmen
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Repare Therapeutics Inc Informationen
BörsenkürzelRPTX
Name des UnternehmensRepare Therapeutics Inc
IPO-datumJun 19, 2020
CEOForte (Steve)
Anzahl der mitarbeiter129
WertpapierartOrdinary Share
GeschäftsjahresendeJun 19
Addresse7210 Frederick-Banting, Suite 100
StadtST-LAURENT
BörseNASDAQ OMX - NASDAQ BASIC
LandCanada
PostleitzahlH4S 2A1
Telefon18574127018
Websitehttps://www.reparerx.com/
BörsenkürzelRPTX
IPO-datumJun 19, 2020
CEOForte (Steve)
Führungskräfte von Repare Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-146.62%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-100.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
--
-100.00%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-146.62%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-100.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Repare Therapeutics Inc?
Die fünf größten Anteilseigner von Repare Therapeutics Inc sind: Dr. Michael Zinda, Ph.D.
Wie viele Institutionen halten Anteile an Repare Therapeutics Inc (RPTX)?
Mit Stand vom 2025Q4 halten 116 Institutionen Anteile an Repare Therapeutics Inc, mit einem Gesamtmarktwert von etwa 24.72M, was 57.35% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um -9601917.00 gestiegen.